Spots Global Cancer Trial Database for A Study of AL2846 on Tolerance and Pharmacokinetics
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of AL2846 on Tolerance and Pharmacokinetics
Official Title: Phase I Study of Tolerance and Pharmacokinetics of AL2846 in Patients With Advanced Cancer
Study ID: NCT02779699
Conditions
Interventions
Study Description
Brief Summary: A study of AL2846,a C-met/Hepatocyte growth factor tyrosine kinase inhibitor,in patients with advanced cancer.
Detailed Description: To study the pharmacokinetic characteristics of AL2846 in the human body; To recommend a reasonable dose and indication for subsequent research.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
